Post-Operative Crohn's Disease: Current and Emerging Management Techniques

Authors

  • Maxime Delisle, MD, FRCPC

DOI:

https://doi.org/10.58931/cibdt.2023.1214

Abstract

Numerous treatment options for Crohn’s disease (CD) have been developed since infliximab was approved in 1998. Treatment practices for CD have also evolved: therapeutic drug monitoring and a treat-to-target approach have replaced symptom control. Despite a decline in surgery rates in Canada and elsewhere in the world, bowel resection is still required for patients with refractory, fistulizing or fibrostenosing CD. Unfortunately, postoperative recurrence (POR) is common; endoscopic recurrence affected 70–90% of patients at the five-year point. However, it is important to note that variations in recurrence were observed between randomized clinical trials (RCTs), referral centre studies and population-based studies. This article will provide an overview of the current monitoring strategies and therapies for CD patients who have undergone a bowel resection.

Author Biography

Maxime Delisle, MD, FRCPC

Dr. Maxime Delisle completed his medical degree and his specialization in gastroenterology at the University of Sherbrooke. He completed his fellowship in advanced inflammatory bowel diseases (IBD) at the University of Calgary. Dr. Delisle is currently an assistant professor at the University of Sherbrooke and an attending gastroenterologist at the Centre Hospitalier Universitaire de Sherbrooke. He is certified in intestinal ultrasound by the International Bowel Ultrasound Group.

References

Garcia NM, Cohen NA, Rubin DT. Treat-to-target and sequencing therapies in Crohn’s disease. United European Gastroenterology Journal. 2022 Dec;10(10):1121-8. doi:10.1002/ueg2.12336 DOI: https://doi.org/10.1002/ueg2.12336

Turner D, Ricciuto A, Lewis A, D’amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021 Apr 1;160(5):1570-83. doi:10.1053/j.gastro.2020.12.031 DOI: https://doi.org/10.1053/j.gastro.2020.12.031

Ma C, Moran GW, Benchimol EI, Targownik LE, Heitman SJ, Hubbard JN, Seow CH, Novak KL, Ghosh S, Panaccione R, Kaplan GG. Surgical rates for Crohn’s disease are decreasing: a population-based time trend analysis and validation study. The American Journal of Gastroenterology. 2017 Dec;112(12):1840. doi:10.1038/ajg.2017.394 DOI: https://doi.org/10.1038/ajg.2017.394

Lowe SC, Sauk JS, Limketkai BN, Kwaan MR. Declining rates of surgery for inflammatory bowel disease in the era of biologic therapy. Journal of Gastrointestinal Surgery. 2021 Jan;25:211-9. doi:10.1007/s11605-020-04832-y DOI: https://doi.org/10.1007/s11605-020-04832-y

Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn’s disease recurrence. Aliment Pharmacol Ther. 2012 Mar;35(6):625-33. doi:10.1111/j.1365-2036.2012.05002.x DOI: https://doi.org/10.1111/j.1365-2036.2012.05002.x

Rutgeerts P, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990 Oct;99(4):956-63. doi:10.1016/0016-5085(90)90613-6. DOI: https://doi.org/10.1016/0016-5085(90)90613-6

Auzolle C, Nancey S, Tran-Minh ML, Buisson A, Pariente B, Stefanescu C, Fumery M, Marteau P, Treton X, Hammoudi N; REMIND Study Group Investigators; Jouven X, Seksik P, Allez M. Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn’s disease: results from a prospective cohort study. Aliment Pharmacol Ther. 2018 Nov;48(9):924-932. doi:10.1111/apt.14944. DOI: https://doi.org/10.1111/apt.14944

Nguyen GC, Loftus EV Jr, Hirano I, et al.; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the management of Crohn’s disease after surgical resection. Gastroenterology. 2017;152:271–275. DOI: https://doi.org/10.1053/j.gastro.2016.10.038

Gionchetti P, Dignass A, Danese S, et al. ECCO 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 2: surgical management and special situations. J Crohns Colitis. 2017;11:135-149. DOI: https://doi.org/10.1093/ecco-jcc/jjw169

Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–s106. DOI: https://doi.org/10.1136/gutjnl-2019-318484

Joustra V, Duijvestein M, Mookhoek A, Bemelman W, Buskens C, Koželj M, Novak G, Hindryckx P, Mostafavi N, D’Haens G. Natural history and risk stratification of recurrent Crohn’s disease after ileocolonic resection: a multicenter retrospective cohort study. Inflammatory Bowel Diseases. 2022 Jan;28(1):1-8. doi:10.1093/ibd/izab044 DOI: https://doi.org/10.1093/ibd/izab044

Ble A, Renzulli C, Cenci F, Grimaldi M, Barone M, Sedano R, Chang J, Nguyen TM, Hogan M, Zou G, MacDonald JK. The relationship between endoscopic and clinical recurrence in postoperative Crohn’s disease: a systematic review and meta-analysis. Journal of Crohn’s and Colitis. 2022 Mar;16(3):490-9. doi:10.1093/ecco-jcc/jjab163 DOI: https://doi.org/10.1093/ecco-jcc/jjab163

Yun Qiu, et al. Fecal Calprotectin for Evaluating Postoperative Recurrence of Crohn’s Disease: A Meta-analysis of Prospective Studies. Inflamm Bowel Dis. 2015 Feb;21(2):315-22. doi:10.1097/MIB.0000000000000262 DOI: https://doi.org/10.1097/MIB.0000000000000262

Florian V, Gilles B, Meunier C, Charlotte C, Gay C, Anne-Laure C, Remi DL, Pauline D, Eddy C, Vahan K, Mialon A. Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn’s Disease. Digestive Diseases and Sciences. 2021 Dec 1;66(12):4429-35. DOI: https://doi.org/10.1007/s10620-020-06751-z

Boube M, Laharie D, Nancey S, Hebuterne X, Fumery M, Pariente B, Roblin X, Peyrin-Biroulet L, Minet-Quinard R, Pereira B, Bommelaer G. Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn’s disease. Digestive and Liver Disease. 2020 Jul 1;52(7):740-4. doi:10.1016/j.dld.2020.03.020 DOI: https://doi.org/10.1016/j.dld.2020.03.020

Yung DE, Har-Noy O, Tham YS, Ben-Horin S, Eliakim R, Koulaouzidis A, Kopylov U. Capsule endoscopy, magnetic resonance enterography, and small bowel ultrasound for evaluation of postoperative recurrence in Crohn’s disease: systematic review and meta-analysis. Inflammatory Bowel Diseases. 2018 Jan 1;24(1):93-100. doi:10.1093/ibd/izx027 DOI: https://doi.org/10.1093/ibd/izx027

Baillet P, Cadiot G, Goutte M, Goutorbe F, Brixi H, Hoeffel C, Allimant C, Reymond M, Obritin-Guilhen H, Magnin B, Bommelaer G. Faecal calprotectin and magnetic resonance imaging in detecting Crohn’s disease endoscopic postoperative recurrence. World Journal of Gastroenterology. 2018 Feb 2;24(5):641. doi:10.3748/wjg.v24.i5.641 DOI: https://doi.org/10.3748/wjg.v24.i5.641

Fraquelli M, Castiglione F, Calabrese E, Maconi G. Impact of intestinal ultrasound on the management of patients with inflammatory bowel disease: how to apply scientific evidence to clinical practice. Digestive and Liver Disease. 2020 Jan 1;52(1):9-18. doi:10.1016/j.dld.2019.10.004 DOI: https://doi.org/10.1016/j.dld.2019.10.004

Shiga H, Abe I, Kusaka J, Shimoyama Y, Moroi R, Kuroha M, Kakuta Y, Kinouchi Y, Masamune A. Capsule endoscopy is useful for postoperative tight control management in patients with Crohn’s disease. Digestive Diseases and Sciences. 2022 Jan 1:1-0. doi:10.1007/s10620-021-06841-6 DOI: https://doi.org/10.1007/s10620-021-06841-6

De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA. Crohn’s disease management after intestinal resection: a randomised trial. Lancet. 2015 Apr 11;385(9976):1406-17. doi:10.1016/S0140-6736(14)61908-5 DOI: https://doi.org/10.1016/S0140-6736(14)61908-5

Buisson A, Blanco L, Manlay L, Reymond M, Dapoigny M, Rouquette O, Dubois A, Pereira B. Top-down versus step-up strategies to prevent postoperative recurrence in Crohn’s disease. Inflammatory Bowel Diseases. 2023 Feb;29(2):185-94. doi:10.1093/ibd/izac065 DOI: https://doi.org/10.1093/ibd/izac065

Rivière P, Pekow J, Hammoudi N, Wils P, De Cruz P, Wang CP, Mañosa M, Ollech J, Allez M, Nachury M, Kamm MA. Comparison of the risk of Crohn’s disease postoperative recurrence between modified Rutgeerts score i2a and i2b categories: An individual patient data meta-analysis. Journal of Crohn’s and Colitis. 2023 Feb;17(2):269-76. doi:10.1093/ecco-jcc/jjac137 DOI: https://doi.org/10.1093/ecco-jcc/jjac137

Bachour SP, Shah RS, Lyu R, Rieder F, Qazi T, Lashner B, Achkar JP, Philpott J, Barnes EL, Axelrad J, Holubar SD. Mild neoterminal ileal post‐operative recurrence of Crohn’s disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesions. Alimentary Pharmacology & Therapeutics. 2022 May;55(9):1139-50. doi:10.1111/apt.16804 DOI: https://doi.org/10.1111/apt.16804

Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009 Feb 1;136(2):441-50. doi:10.1053/j.gastro.2008.10.051 DOI: https://doi.org/10.1053/j.gastro.2008.10.051

Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection. Gastroenterology. 2016 Jun 1;150(7):1568-78. doi:10.1053/j.gastro.2016.02.072 DOI: https://doi.org/10.1053/j.gastro.2016.02.072

Yanai H, Kagramanova A, Knyazev O, Sabino J, Haenen S, Mantzaris GJ, Mountaki K, Armuzzi A, Pugliese D, Furfaro F, Fiorino G. Endoscopic Postoperative Recurrence in Crohn’s Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study. Journal of Crohn’s and Colitis. 2022 Dec;16(12):1882-92. doi:10.1093/ecco-jcc/jjac100 DOI: https://doi.org/10.1093/ecco-jcc/jjab232.511

Beelen EM, Nieboer D, Arkenbosch JH, Regueiro MD, Satsangi J, Ardizzone S, López-Sanromán A, Savarino E, Armuzzi A, van der Woude CJ, de Vries AC. Risk prediction and comparative efficacy of Anti-TNF vs thiopurines, for preventing postoperative recurrence in Crohn’s disease: a pooled analysis of 6 trials. Clinical Gastroenterology and Hepatology. 2022 Dec 1;20(12):2741-52. doi:10.1016/j.cgh.2021.10.021 DOI: https://doi.org/10.1016/j.cgh.2021.10.021

Glick LR, Sossenheimer PH, Ollech JE, Cohen RD, Hyman NH, Hurst RD, Rubin DT. Low-dose metronidazole is associated with a decreased rate of endoscopic recurrence of Crohn’s disease after ileal resection: a retrospective cohort study. Journal of Crohn’s and Colitis. 2019 Sep 19;13(9):1158-62. doi:10.1093/ecco-jcc/jjz047 DOI: https://doi.org/10.1093/ecco-jcc/jjz047

Dragoni G, Ding N, Gecse KB, Mansfield JC, Kopylov U, Beaugerie L, Bossuyt P, Sebastian S, Milla M, Bagnoli S, Yassin NA. The prevention and management of Crohn’s disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey. European Journal of Gastroenterology & Hepatology. 2020 Feb 8;32(8):1062-6. doi:10.1097/MEG.0000000000001729 DOI: https://doi.org/10.1097/MEG.0000000000001729

Published

2023-06-28

How to Cite

1.
Delisle M. Post-Operative Crohn’s Disease: Current and Emerging Management Techniques. Can IBD Today [Internet]. 2023 Jun. 28 [cited 2024 Nov. 23];1(2):26–31. Available from: https://canadianibdtoday.com/article/view/1-2-delisle

Issue

Section

Articles